EN DE

Osteonic Co (226400) Fair Value & Analysis

Healthcare · KR · Market cap 90.3B KRW

OC Osteonic Co 226400 · KQ
Price5,040 KRW
Fair Value4,989 KRW
Upside-1.0%
Quality47/100
Watch Osteonic Co for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Solidly profitable · 19.3% net margin
Low debt · generates free cash flow
Ranks above peers (7/9)
Moderate moat 61/100
Evidence: High Range 3,147 KRW – 9,443 KRW Share as image

Fair value as of: Jul 20, 2026

From 23 valuation models · updated 21 days ago

Fair value updated Jul 20, 2026, revised from 5,001 KRW to 4,989 KRW (−0.2%) since Jul 7, 2026. Share price +12.0% over the past month.

Below-average quality, currently priced close to our fair value.

What matters now

  • The model range is unusually wide (3,147 KRW to 9,443 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

8,390 KRW 2,340 KRW Fair Value 4,989 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.

How to read this chart

60‑month range 2,340 KRW – 8,390 KRW · fair‑value band 3,147 KRW – 9,443 KRW · the 5,040 KRW price screens above the 4,989 KRW fair value. Dashed = 300-day average. As of Jul 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Osteonic Co (226400) currently trades at 5,040 KRW, while our model-based Fair Value estimate is 4,989 KRW, implying the stock looks roughly 1.0% fairly valued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Osteonic Co generated revenue of 48.8B KRW at a net margin of 19.3%. Revenue grew 35.4% year over year. It earns a return on equity of 14.3%. Net debt stands at 3.4B KRW. Fundamentals as of Jul 20, 2026

Our scenario range runs from 3,147 KRW (bear case) to 9,443 KRW (bull case); at 5,040 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -1%, 226400 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 559.50 KRW 603.68 KRW 692.98 KRW 80
ROIC Compounder 4,943 KRW 6,738 KRW 8,283 KRW 72
Growth-Adj P/E 7,811 KRW 11,159 KRW 14,507 KRW 68
All 23 models by family
DCF Models
FCF DCF 562.75 KRW 594.07 KRW 693.80 KRW 38
Owner Earnings 2,263 KRW 4,503 KRW 9,203 KRW 31
5Y Revenue Exit 2,061 KRW 3,636 KRW 6,968 KRW 39
5Y EBITDA Exit 2,651 KRW 4,828 KRW 9,118 KRW 41
5Y P/E Exit 3,487 KRW 8,146 KRW 14,664 KRW 38
10Y Revenue Exit 1,571 KRW 3,860 KRW 5,634 KRW 36
10Y EBITDA Exit 2,087 KRW 5,129 KRW 10,787 KRW 37
10Y P/E Exit 2,698 KRW 6,931 KRW 14,279 KRW 35
Earnings-Based
Graham-Dodd 2,542 KRW 17,726 KRW 24,876 KRW 54
Lynch FV 7,114 KRW 10,163 KRW 13,212 KRW 50
PEG = 1.0 7,114 KRW 10,163 KRW 13,212 KRW 46
EPV 4,125 KRW 4,728 KRW 5,255 KRW 59
Multiples
P/E Multiple 3,925 KRW 5,233 KRW 6,541 KRW 63
P/S Multiple 2,036 KRW 2,715 KRW 3,394 KRW 58
P/B Multiple 4,540 KRW 6,053 KRW 7,566 KRW 55
EV/EBIT 3,822 KRW 4,927 KRW 6,031 KRW 53
EV/EBITDA 3,325 KRW 4,264 KRW 5,204 KRW 54
EV/Revenue 2,409 KRW 3,223 KRW 4,038 KRW 43
Asset-Based
NCAV (Graham) 1,681 KRW 2,253 KRW 3,363 KRW 50
Growth DCF
Growth DCF 559.50 KRW 603.68 KRW 692.98 KRW 80
Economic Profit
Residual Income 3,044 KRW 3,500 KRW 6,654 KRW 61
ROIC Compounder 4,943 KRW 6,738 KRW 8,283 KRW 72
Growth Earnings
Growth-Adj P/E 7,811 KRW 11,159 KRW 14,507 KRW 68

Widest divergence: Growth Earnings (11,159 KRW) versus Growth DCF (603.68 KRW). Highest evidence: Growth DCF (80).

Notify me when 226400 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 48.8B KRW
Revenue growth (YoY) +35.4%
Net margin 19.3%
Return on equity 14.3%
Free cash flow 65.1M KRW FY2025
Operating margin 18.1%
More key figures
EPS growth (YoY) +242%
Net debt 3.4B KRW FY2025

Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 47/100

Of which business quality 49 · Market factors (momentum, volatility) 25

Profitability 47
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 34
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 4
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 16
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Osteonic Co., Ltd. develops, manufactures, and sells bone fixation systems. It offers CMF systems, including neuro plating systems, maxillofacial plating systems, mandible plating systems, IMF screws, power screw drivers, 90 angled screw driver, customized neuro 3D mesh, and mandible reconstruction plates under the OPTIMUS and Real FIT brand names; and …

Full company description

Osteonic Co., Ltd. develops, manufactures, and sells bone fixation systems. It offers CMF systems, including neuro plating systems, maxillofacial plating systems, mandible plating systems, IMF screws, power screw drivers, 90 angled screw driver, customized neuro 3D mesh, and mandible reconstruction plates under the OPTIMUS and Real FIT brand names; and biodegradable CMF plating systems under the BIOBSORB name. The company also provides products for trauma and extremities, which include hand plating, wrist plating, foot plating, and hallux valgus systems, as well as cannulated screws under the SIGNEX name. In addition, it offers dental products, such as mini screws, GBR systems, palatal plates, power drivers, and palatal expanders under the Optimus D name; veterinary systems; and sports medicines under the KINEX brand name. The company serves physicians and university hospitals. Osteonic Co., Ltd. was founded in 2012 and is based in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Osteonic Co reported revenue of 45.4B KRW in FY2025 versus 15.6B KRW in FY2021, a compound +30.6%/yr. Reported net income was 7.5B KRW in FY2025.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
45.4B KRW
Latest YoY
+32.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+31.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+29.2%
Avg. growth/yr (10Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+29.2%
Revenue +30.6%/yr
FY21 15.6B KRW
FY22 19.8B KRW
FY23 27.8B KRW
FY24 34.2B KRW
FY25 45.4B KRW
Net income
FY21 −2.9B KRW
FY22 836M KRW
FY23 3.7B KRW
FY24 5.6B KRW
FY25 7.5B KRW

Watch 226400: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Osteonic Co Fair Value". https://www.fairvalue-calculator.com/stock/226400

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 47 · Below median
Fair Value upside −1% · Above median
Return on equity (TTM) 14% · Top 25%
Return on assets 6% · Top 25%
Net margin (TTM) 19% · Top 25%
Operating margin (TTM) 18% · Top 25%
Revenue growth 35% · Top 25%
Debt / equity 0.06× · Higher than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/FCF 1.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 32 · sector 0
FUTURE 100 · sector 29
PAST 57 · sector 8
HEALTH 97 · sector 97
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
DexCom, Inc DXCM $74.96 $38.95 -48%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%

Compare Osteonic Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Osteonic Co (226400) overvalued or undervalued?
As of Jul 20, 2026, our model estimates a fair value of 4,989 KRW versus a price of 5,040 KRW, about −1% (fairly valued).
What is the fair value of 226400?
Our model-based fair value for Osteonic Co is 4,989 KRW (as of Jul 20, 2026), built from audited fundamentals. The current price is 5,040 KRW.
What is the quality score of 226400?
Osteonic Co has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Osteonic Co (226400)?
Osteonic Co reported trailing-twelve-month revenue of about 48.8B KRW (latest available figure, as of Jul 20, 2026).
What is the net profit margin of 226400?
The net profit margin of Osteonic Co is about 19.3%, meaning it keeps roughly 19.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Osteonic Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.